<DOC>
	<DOCNO>NCT00899509</DOCNO>
	<brief_summary>This research trial study deoxyribonucleic acid ( DNA ) tumor tissue woman node-positive breast cancer see genetic factor relate patient 's response chemotherapy . DNA analysis tumor tissue may help doctor predict well patient respond treatment certain chemotherapy drug .</brief_summary>
	<brief_title>Gene Expression Profiling Genetic Analysis Tissues From Patients With Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : 1 . To determine amplification and/or overexpression erbB-2 associate either additional less benefit increase dos doxorubicin four cycle paclitaxel . 2 . To determine abnormality p53 ( mutation , deletion , protein stabilization ) associate either additional less benefit increase dos doxorubicin four cycle paclitaxel . 3 . To compare method analysis erbB-2 p53 , use common mean assay biomarkers , order determine whether one method predictive clinical outcome another , whether method complementary . 4 . To identify biomarkers use individually tailor use adjuvant dose-dense therapy . 5 . To identify group patient poor prognosis , despite adjuvant chemotherapy , prospectively target new approach adjuvant treatment . 6 . To identify biomarkers use individually tailor use adjuvant paclitaxel therapy . 7 . To identify group patient poor prognosis despite adjuvant chemotherapy prospectively target new approach adjuvant treatment . 8 . To determine intrinsic subtype , determine PAM50 assay , associate benefit paclitaxel ( C9344 ) dose dense chemotherapy ( C9741 ) regardless clinical estrogen receptor ( ER ) human epidermal growth factor receptor 2 ( HER2 ) status . 9 . To determine intrinsic subtype associate benefit paclitaxel dose dense chemotherapy HER2 negative subset , define tissue microarray ( TMA ) analysis HER2 complete section B2 B3 protocol . 10 . To determine relapse score , determine PAM50 assay , associate benefit paclitaxel dose dense chemotherapy regardless clinical ER HER2 status . 11 . To determine relapse score associated benefit paclitaxel dose dense chemotherapy HER2 negative subset . 12 . To evaluate association PAM50-defined proliferation score benefit paclitaxel dose dense chemotherapy . 13 . To evaluate whether patient identify basal breast cancer PAM50 assay benefit paclitaxel . SECONDARY OBJECTIVES : 1 . To compare performance PAM50-defined intrinsic subtypes subtype diagnosis determine antibody panel , develop section B2 B3 protocol , predict benefit paclitaxel dose dense chemotherapy HER2 negative subset . 2 . To evaluate prognostic value PAM50-defined relapse score patient receive paclitaxel therapy ( C9344 ) . 3 . To investigate performance multivariate model include proliferation score risk relapse predict benefit paclitaxel dose dense chemotherapy . OUTLINE : Formalin-fixed , paraffin-embedded tissue block analyze amplification and/or overexpression erbB-2 ( HER-2/neu ) mutation deletion p53 fluorescent situ hybridization ( FISH ) immunohistochemistry .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Registration CALGB 9344 9741 2 . Samples collect , ship store appropriately CALGB Pathology Coordinating Office 3 . Institutional Review Board ( IRB ) review approval institution laboratory work perform require . 4 . Informed consent : The CALGB require separate consent form sign study . The subject population study protocol include patient select one follow CALGB treatment protocol : CALGB 9344 9741 . All patient sign write informed consent document meeting federal , state institutional guideline part entry trial . All sample study obtain stored part patient 's respective treatment trial . The data obtain patient 's record use obtain appropriate clinical information . In instance patient contact directly . There physical , psychological , social legal risk associate study . No invasive procedure recommend request . All appropriate necessary procedure utilized maintain confidentiality . All patient sample submit analysis CALGB ID number use identify specimen . This study require direct patient contact specific risk benefit individual involve trial anticipate . It likely , however , tIt likely , however , information gain substantially help similar patient future .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>